Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4.64
SNSS's Cash to Debt is ranked higher than
66% of the 1281 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. SNSS: 4.64 )
SNSS' s 10-Year Cash to Debt Range
Min: 2.18   Max: No Debt
Current: 4.64

Equity to Asset 0.31
SNSS's Equity to Asset is ranked higher than
57% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SNSS: 0.31 )
SNSS' s 10-Year Equity to Asset Range
Min: -2.09   Max: 0.87
Current: 0.31

-2.09
0.87
F-Score: 3
Z-Score: -15.57
M-Score: -3.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -785.54
SNSS's Operating margin (%) is ranked higher than
60% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -83.68 vs. SNSS: -785.54 )
SNSS' s 10-Year Operating margin (%) Range
Min: -64863.64   Max: -169.03
Current: -785.54

-64863.64
-169.03
Net-margin (%) -749.95
SNSS's Net-margin (%) is ranked higher than
59% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. SNSS: -749.95 )
SNSS' s 10-Year Net-margin (%) Range
Min: -74506.06   Max: -166.44
Current: -749.95

-74506.06
-166.44
ROE (%) -406.94
SNSS's ROE (%) is ranked higher than
50% of the 1160 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. SNSS: -406.94 )
SNSS' s 10-Year ROE (%) Range
Min: -1198.61   Max: -57.33
Current: -406.94

-1198.61
-57.33
ROA (%) -81.95
SNSS's ROA (%) is ranked higher than
58% of the 1286 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. SNSS: -81.95 )
SNSS' s 10-Year ROA (%) Range
Min: -448.13   Max: -39.99
Current: -81.95

-448.13
-39.99
ROC (Joel Greenblatt) (%) -116090.21
SNSS's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 1251 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. SNSS: -116090.21 )
SNSS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -138593.85   Max: -460.2
Current: -116090.21

-138593.85
-460.2
Revenue Growth (3Y)(%) -6.50
SNSS's Revenue Growth (3Y)(%) is ranked higher than
73% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. SNSS: -6.50 )
SNSS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 74.5
Current: -6.5

0
74.5
EBITDA Growth (3Y)(%) 15.90
SNSS's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -7.20 vs. SNSS: 15.90 )
SNSS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -59.5   Max: 15.9
Current: 15.9

-59.5
15.9
EPS Growth (3Y)(%) 18.70
SNSS's EPS Growth (3Y)(%) is ranked higher than
89% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. SNSS: 18.70 )
SNSS' s 10-Year EPS Growth (3Y)(%) Range
Min: -60.4   Max: 20.5
Current: 18.7

-60.4
20.5
» SNSS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SNSS Guru Trades in Q1 2014

Jim Simons 23,214 sh (New)
Steven Cohen 502,900 sh (New)
Jean-Marie Eveillard 219,557 sh (-8.50%)
» More
Q2 2014

SNSS Guru Trades in Q2 2014

Steven Cohen 468,500 sh (unchged)
Jim Simons 22,886 sh (-1.41%)
Jean-Marie Eveillard 200,000 sh (-8.91%)
» More
Q3 2014

SNSS Guru Trades in Q3 2014

Jean-Marie Eveillard Sold Out
Jim Simons Sold Out
Steven Cohen Sold Out
» More
Q4 2014

SNSS Guru Trades in Q4 2014

Jean-Marie Eveillard 1,414,276 sh (New)
Paul Tudor Jones 17,516 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SNSS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.50
SNSS's P/B is ranked higher than
52% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. SNSS: 11.50 )
SNSS' s 10-Year P/B Range
Min: 1.01   Max: 297.5
Current: 11.5

1.01
297.5
P/S 26.50
SNSS's P/S is ranked higher than
62% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 30.13 vs. SNSS: 26.50 )
SNSS' s 10-Year P/S Range
Min: 0.9   Max: 157.25
Current: 26.5

0.9
157.25
EV-to-EBIT -3.16
SNSS's EV-to-EBIT is ranked higher than
71% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SNSS: -3.16 )
SNSS' s 10-Year EV-to-EBIT Range
Min: -11.7   Max: 2.4
Current: -3.16

-11.7
2.4
Current Ratio 1.59
SNSS's Current Ratio is ranked higher than
58% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. SNSS: 1.59 )
SNSS' s 10-Year Current Ratio Range
Min: 1.19   Max: 7.2
Current: 1.59

1.19
7.2
Quick Ratio 1.59
SNSS's Quick Ratio is ranked higher than
60% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. SNSS: 1.59 )
SNSS' s 10-Year Quick Ratio Range
Min: 1.19   Max: 7.2
Current: 1.59

1.19
7.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.40
SNSS's Price/Net Cash is ranked higher than
74% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 93.33 vs. SNSS: 12.40 )
SNSS' s 10-Year Price/Net Cash Range
Min: 1.91   Max: 33.79
Current: 12.4

1.91
33.79
Price/Net Current Asset Value 12.40
SNSS's Price/Net Current Asset Value is ranked higher than
73% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 39.86 vs. SNSS: 12.40 )
SNSS' s 10-Year Price/Net Current Asset Value Range
Min: 1.86   Max: 18.26
Current: 12.4

1.86
18.26
Price/Tangible Book 11.80
SNSS's Price/Tangible Book is ranked higher than
57% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. SNSS: 11.80 )
SNSS' s 10-Year Price/Tangible Book Range
Min: 1.6   Max: 273.5
Current: 11.8

1.6
273.5
Price/Median PS Value 2.90
SNSS's Price/Median PS Value is ranked higher than
68% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. SNSS: 2.90 )
SNSS' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 5.53
Current: 2.9

0.1
5.53
Earnings Yield (Greenblatt) -33.20
SNSS's Earnings Yield (Greenblatt) is ranked lower than
56% of the 1264 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. SNSS: -33.20 )
SNSS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -33.5   Max: 16670.9
Current: -33.2

-33.5
16670.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RYIN.Germany,
Sunesis Pharmaceuticals, Inc., was incorporated in the state of Delaware on February 10, 1998. It is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. It currently focuses on the development of vosaroxin for the treatment of acute myeloid leukemia, or AML. Vosaroxin is a first-in-class anti-cancer quinolone derivative, or AQD—a class of compounds that has not been used previously for the treatment of cancer. AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. It has built an experienced cancer drug development organization committed to advancing vosaroxin in multiple indications to improve the lives of people with cancer. In December 2010, the Company commenced enrollment of a Phase 3, multi-national, randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial. The VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, a widely used chemotherapy in AML, on overall survival as compared to placebo in combination with cytarabine. The Company owns development and commercialization rights to vosaroxin. It faces competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching, developing and marketing products designed to address the treatment of cancer, including AML and ovarian cancer. In addition to regulations in the United States, the Company is subject to foreign regulations governing clinical trials and commercial sales and distribution of vosaroxin or its future drug candidates, if any.
» More Articles for SNSS

Headlines

Articles On GuruFocus.com
comment on SNSS Mar 02 2013 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 
Weekly CFO Buys Highlight: SNSS, INUV, CEP, CMTL, SURW Oct 10 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
cooldecency99 note on SNSS May 01 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Apr 29 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 
Most Trade Guru Stocks: Citigroup Inc., Bank of America Corp., Alcoa Inc., Sunesis Pharmaceuticals Dec 12 2009 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 16 2009 
Sunesis Reports Financial Results for the Second Quarter 2009 Jul 29 2009 

More From Other Websites
4 Biotech Stocks Under $10 to Trade for Breakouts Mar 24 2015
SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Mar 23 2015
SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 12 2015
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Recent... Mar 12 2015
Sunesis reports 4Q loss Mar 12 2015
Sunesis reports 4Q loss Mar 12 2015
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Recent... Mar 12 2015
3 Biotech stocks Under $10 to Trade for Breakouts Mar 05 2015
Sunesis to Host Conference Call on March 12th to Discuss Fourth Quarter and Full-Year 2014 Financial... Mar 05 2015
Sunesis Announces Amendment to Loan Agreement Mar 02 2015
Sunesis Announces Amendment to Loan Agreement Mar 02 2015
Sunesis to Present at Upcoming Investor Conferences Feb 24 2015
Sunesis to Present at Upcoming Investor Conferences Feb 24 2015
4 Health Care Stocks Under $10 to Watch: ImmunoGen, Bacterin and More Feb 19 2015
Sunesis to Present at the 2015 RBC Capital Markets' Global Healthcare Conference Feb 18 2015
Sunesis to Present at the 2015 RBC Capital Markets' Global Healthcare Conference Feb 18 2015
The Life Sciences Report Releases 2015 Small-Cap Biotech Watchlist Panel Comments Feb 03 2015
BTIG Initiates Coverage On Sunesis Pharmaceuticals, Believes Company 'Will Be Breakeven By 2017' Jan 05 2015
SUNESIS PHARMACEUTICALS INC Financials Dec 16 2014
Sunesis Announces Presentation of Positive Updated Results from Ongoing MD Anderson-Sponsored Trial... Dec 08 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK